NTLA Intellia Therapeutics
- 21.460
- -0.920-4.11%
- 21.500
- +0.040+0.19%
Intellia Therapeutics News
Express News | RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $54
Intellia Therapeutics Analyst Ratings
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Intellia Therapeutics: A Strong Buy on Groundbreaking Gene Editing Advances and Positive Clinical Trials
RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk
Barclays Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : RBC Cuts Target Price to $54 From $60
Intellia Therapeutics | 10-Q: Q2 2024 Earnings Report
Intellia Hereditary Angioedema Candidate Meets Phase 2 Primary Endpoint
Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Progress and Positive KOL Feedback
Express News | Intellia Therapeutics Q2 2024 GAAP EPS $(1.52) Misses $(1.24) Estimate, Sales $6.957M Miss $19.162M Estimate
Express News | Intellia Therapeutics Inc: Ended Q2 With About $940 Mln in Cash
Intellia Therapeutics GAAP EPS of -$1.52 Misses by $0.29, Revenue of $6.96M Misses by $11.29M
Express News | Intellia Therapeutics Q2 Operating Income USD -139.043 Million
Intellia Therapeutics 2Q Loss $147M >NTLA
Press Release: Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Express News | Intellia Therapeutics Q2 Collaboration Revenue USD 6.957 Million
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics Q2 2024 Earnings Preview
Analysis
Price Target
No Data
